Redox-inactive analogue of tocotrienol as a potential anti-cancer agent

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 496-501

  Yano, Tomohiro ^a   Sato, Ayami ^a   Sekine, Miki ^a   Virgona, Nantiga ^a   Ota, Masako ^a  

^a TOYO UNIVERSITY   (Japan)

Author keywords

Anticancer activity; Non antioxidant; Redox inactive analogue; Tocotrienol

Indexed keywords

ALPHA TOCOTRIENOL; ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOXIA INDUCIBLE FACTOR; PROTEIN BCL XL; PROTEIN KINASE B; STAT3 PROTEIN; TAMOXIFEN; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BIOAVAILABILITY; CANCER PREVENTION; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CYTOTOXICITY; HYPOXIA; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; ONCOGENE SRC; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HUMANS; MUTATION; NEOPLASMS; ONCOGENE PROTEIN P21(RAS); OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; TOCOTRIENOLS;

EID: 84876703811     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313030012     Document Type: Review

References (75)

1. Sure, B. Dietary requirements for reproduction: II. The existence of a specific vitamin for reproduction. J. Biol. Chem., 1924, 58 (3), 693-709.
2. Valentin, H.E.; Qi, Q. Biotechnological production and application of vitamin E: current state and prospects. Appl. Microbiol. Biotechnol., 2005, 68 (4), 436-444.
3. Sundram, K.; Thiagarajan, T.; Gapor, A.; Basiron, Y. Palmtocotrienols: new antioxidants for the new millennium. Inform., 2002, 13, 634-640.
4. Serbinova, E.; Kagan, V.; Han, D.; Packer, L. Free radical recycling and intramembrane mobility in the antioxidant properties of α-tocopherol and α-tocotrienol. Free Radic. Biol. Med., 1991, 10 (5), 263-275.
5. He, L.; Mo, H, Hadisusilo, S.; Qureshi, A.A.; Elson, C.E. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J. Nutr., 1997, 127 (5), 668-674.
6. Azzi, A.; Stocker, A. Vitamin E: non-antioxidant roles. Prog. Lipid Res., 2000, 39 (3), 231-255.
7. Kayden, H.J.; Traber, M.G. Absorption, lipoprotein transport and regulation of plasma concentrations of vitamin E in humans. J. Lipid Res., 1993, 34 (3), 343-358.
8. Yap, S.P.; Yuen, K.H.; Wong, J.W. Pharmacokinetics and bioavailability of alpha-, gamma-, and delta-tocotrienols under different food status. J. Pharm. Pharmacol., 2001, 53 (1), 67-71.
9. Mustacich, D.J.; Bruno, R.S.; Traber, M.G. Vitamin E. Vitam. Horm., 2007, 76, 1-21.
10. Brigelius-Flohe, R.; Traber, M.G. Vitamin E: function and metabolism. FASEB. J., 1999, 13 (10), 1145-1155.
11. Lodge, J.K.; Ridlington, J.; Leonard, S.; Vaule, H.; Traber, M.G. Alpha- and gamma-tocotrienols are metabolized to carboxyethyl-hydroxychroman derivatives and excreted in human urine. Lipids, 2001, 36(1), 43-48.
12. Kamal-Eldin, A.; Appelqvist, L.A. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids, 1996, 31 (7) 671-701.
13. Niki, E.; Kawakami, A.; Satio, M.; Yamamto, Y.; Tsuchiya, J.; Kamiya, Y. Effect of phytyl side chain of vitamin E on iots antioxidant activity. J. Biol. Chem., 1985, 260 (4), 2191-2196.
14. Burton, G.W.; Ingold, K.U. Vitamin E as an in vitro and in vivo antioxidant. Ann. N. Y. Acad. Sci., 1989, 570, 7-22.
15. Nesaretnam, K.; Devasagayam, T.P.; Singh, B.B.; Basiron, Y. Influence of palm oil or its tocotrienol-rich fraction on the lipid peroxidation potential of rat liver mitochondria and microsomes. Biochem. Mol. Biol. Int., 1993, 30 (1), 159-167.
16. Serbinova, E.; Kagan, V.; Han, D.; Packer, L. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic. Biol. Med., 1991, 10 (5), 263-275.
17. Ling, T.M.; Luk, S.U.; Al-Ejeh, F.; Khanna, K.K. Toctrienol as a potential anticancer agent. Carcinogenesis, 2012, 33(5), 233-239.
18. McIntyre, B.S.; Briski, K.P.; Gapor, A.; Sylvester, P.W. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc. Soc. Exp. Biol. Med., 2000, 224 (4), 292-301.
19. Komiyama, K.; Iizuka, K.; Yamaoka, M.; Watanabe, H.; Tsuchiya, N.; Umezawa, I. Studies on the biological activity of tocotrienols. Chem. Pharm. Bull., 1989, 37 (5), 1369-1371.
20. Xu, W.L.; Liu, J.R.; Liu, H.K.; Qi, K.Y.; Sun, X.R.; Sun, W.G. Inhibition of proliferation and induction of apoptosis by gamma-tocotrienol in human colon carcinoma HT-29 cells. Nutrition, 2009, 25(5), 555-566.
21. Pierpaoli, E.; Viola, V.; Pilolli, F.; Piroddi, M.; Galli, F.; Provinciali, M. Gamma- and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of Her-2/neu expression. Life Sci., 2010, 86(17-18), 668-675.
22. Samant, G.V.; Wali, V.B.; Sylvester, P.W. Anti-proliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif., 2010, 43(1), 77-83.
23. Srivastava, J.K.; Gupta, S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem. Biophys. Res. Commun., 2006, 346 (2), 447-453.
24. Eitsuka, T.; Nakagawa, K.; Miyazawa, T. Down-regulation of telomerase activity in DLD-1 human colorectal adenocarcinoma cells by tocotrienol. Biochem. Biophys. Res. Commun., 2006, 348 (1),170-175.
25. Chang, P.N.; Yap, W.N.; Lee, D.T.; Ling, M.T.; Wong, Y.C.; Yap, Y.L. Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutr. Cancer, 2009, 61(3), 357-366.
26. Crowell, P.L.; Chang, R.R.; Ren, Z.B.; Elson, C.E.; Gould, M.N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J. Biol. Chem., 1991, 266 (26), 17679-17685.
27. McAnally, J.A.; Gupta, J.; Sodhani, S.; Bravo, L.; Mo, H. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp. Biol. Med (Maywood)., 2007, 232(4), 523-531.
28. Park, S.K.; Sanders, B.G.; Kline, K. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. Breast Cancer Res. Treat., 2010, 124(2), 361-375.
29. Shirode, A.B.; Sylvester, P.W. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed. Pharmacother., 2010, 64(5), 327-332.
30. Yerbes, R.; Palacios, C; López-Rivas, A. The therapeutic potential of TRAIL receptor signalling in cancer cells. Clin. Transl. Oncol., 2011, 13(12), 839-847.
31. Fogg, V.C.; Lanning, N.J.; Mackeigan, J.P. Mitochondria in cancer: at the crossroads of life and death. Chin. J. Cancer, 2011, 30(8), 526-539.
32. Hedskog, L.; Zhang, S.; Ankarcrona, M. Strategic Role for mitochondria in Alzheimer's Disease and cancer. Antioxid., Redox Signal., 2012, 16(12), 1476-1491.
33. Agarwal, M.K.; Agarwal, M.L.; Athar, M.; Gupta, S. Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. Cell Cycle, 2004, 3 (2), 205-211.
34. Ahn, K.S.; Sethi, G.; Krishnan, K.; Aggarwal, B.B. Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. J. Biol. Chem., 2007, 282 (1), 809-820.
35. Wali, V.B.; Bachawal, S.V.; Sylvester, P.W. Endoplasmic reticulum stress mediates gamma-tocotrienol-induced apoptosis in mammary tumor cells. Apoptosis, 2009, 14 (11), 1366-1377.
36. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86 (3), 353-364.
37. Skobe, M.; Rockwell, P.; Goldstein, N.; Vosseler, S.; Fusenig, N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med., 1997, 3 (11), 1222-1227.
38. Shojaei, F. Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett., 2012, 320(2), 130-137.
39. Belotti, D.; Foglieni, C; Resovi, A.; Giavazzi, R.; Taraboletti, G. Targeting angiogenesis with compounds from the extracellular matrix. Int. J. Biochem. Cell Biol., 2011, 43(12), 1674-1685.
40. Nakagawa, K.; Shibata, A.; Yamashita, S.; Tsuzuki, T.; Kariya, J.; Oikawa, S.; Miyazawa, T. In vivo angiogenesis is suppressed by unsaturated vitamin E. J. Nutr., 2007, 137 (8), 1938-1943.
41. Neuzil, J. Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumor activity. Br. J.Cancer, 2003, 89 (10),1822-1826.
42. Birringer, M.; EyTina, J.H.; Salvatore, B.A.; Neuzil, J. Vitamin E analogues as inducers of apoptosis: structure-function relation. Br. J. Cancer, 2003, 88 (12), 1948-1955.
43. Rohlena, J.; Dong, L.F.; Kluckova, K.; Zobalova, R.; Goodwin, J.; Tilly, D.; Stursa, J.; Pecinova, A.; Philimonenko, A.; Hozak, P.; Banerjee, J.; Ledvina, M.; Sen, C.K.; Houstek, J.; Coster, M.J.; Neuzil, J. Mitochondrially targeted a-tocopheryl succinate is antiangiogenic: potential benefit against tumor angiogenesis but caution against wound healing. Antioxid. Redox Signal., 2011, 15(12), 2923-2935.
44. Faris, M.W.; Fortuna, M.B.; Everett, C.K.; Smith, J.D.; Trent, D.F.; Djuric, Z. The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds. Cancer Res., 1994, 54 (13), 3346-3351.
45. Yano, T.; Yano, Y.; Yajima, S.; Kumadaki, I.; Ichikawa, T.; Otani, S.; Hagiwara, K. The suppression of ornithine decarboxylase expression and cell proliferation at the promotion stage of lung tumorigenesis in mice by alpha-tocopheryloxybutyric acid. Biochem. Pharmacol., 2001, 61 (9), 1177-1181.
46. Yano, Y.; Satoh, H.; Fukumoto, K.; Kumadaki, I.; Ichikawa, T.; Yamada, K.; Hagiwara, K.; Yano, T. Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-alpha-tocotrienol, a redox-silent derivative of alpha-tocotrienol. Int. J. Cancer, 2005, 115 (5), 839-846.
47. Behery, F.A.; Elnagar, A.Y.; Akl, M.R.; Wali, V.B.; Abuasal, B.; Kaddoumi, A.; Sylvester, P.W.; El Sayed, K.A. Redox-silent tocotrienol esters as breast cancer proliferation and migration inhibitors. Bioorg. Med. Chem., 2010, 18(22), 8066-8075.
48. Singh, R.P.; Kumar, R.; Kapur, N. Molecular regulation of cholesterol biosynthesis: implications in carcinogenesis. J. Environ. Pathol. Toxicol. Oncol., 2003, 22 (2), 75-92.
49. Kato, K.; Cox, A.D.; Hiasaka, M.M.; Graham, S.M.; Buss, J.E.; Der, C.J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 1992, 89 (14), 6403-6407.
50. Packer, L.; Weber, S.U.; Rimbach, G. Molecular aspects of alpha-tocotrienol antioxidant action and cell signaling. J. Nutr., 2001, 131 (2), 369S-373S.
51. Elson, C.E.; Peffley, D.M.; Hentosh, P.; Mo, H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc. Soc. Exp. Biol. Med., 1999, 221 (4), 294-311.
52. Bucher, M.J.; Morisset, J.; Vachon, P.H.; Reed, J.C., Laine, J.; Rivard, N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell Biochem., 2000, 79 (3), 355-369.
53. Kato-Stankiewicz, J.; Hakimi, I.; Zhi, G.; Zhang, J.; Serebriiskii, I.; Guo, L.; Edamatsu, H.; Koide, H.; Menon S.; Eckl, R.; Sakamuri, S.; Lu, Y.; Chen, Q.Z.; Agarwal, S.; Baumbach, W.R.; Golemis, E.A.; Tamanoi, F.; Khazak, V. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. 2002, 99 (22), 14398-14403.
54. Fritz, G.; Just, I.; Kaina, B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer, 1999, 81 (5), 682-687.
55. Kusama, T.; Mukai, M.; Iwasaki, T.; Tatsuta, M.; Matsumoto, Y.; Akedo, H.; Nakamura, H. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res., 2001, 61 (12), 4885-4891.
56. Hall, A. Rho GTPases and the actin cytoskeleton. Science, 1998, 279 (5350), 509-514.
57. Ownby, S.E.; Hohl, R.J. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids, 2002, 37 (2), 185-192.
58. Martin, SS.; Ridgeway, A.G.; Pinkas, J.; Lu, Y.; Reginato, M.J.; Koh, E.Y.; Michelman, M.; Daley, G.Q.; Brugge, J.S.; Leder, P. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene, 2004, 23 (26), 4641-4645.
59. Sen, CK.; Khanna, S.; Roy, S.; Packer, L. Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells. J. Biol. Chem., 2000, 275 (17), 13049-13055.
60. Ishizawar, R.; Parsons, S.J. c-Src and cooperating partners in human cancer. Cancer Cell, 2004, 6 (3), 209-214.
61. Tsao, A.S.; He, D.; Saigal, B.; Liu, S., Lee J.J.; Bakkannagari, S.; Ordonez, N.G.; Hong, W.K.; Wistuba, I.; Johnson, F.M. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol. Cancer Ther., 2007, 6 (7), 1962-1972.
62. Kashiwagi, K.; Virgona, N.; Harada, K.; Kido, W.; Yano, Y.; Ando, A.; Hagiwara, K.; Yano, T. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci., 2009, 84 (19-20), 650-656.
63. Yano, T.; Kashiwagi, K.; Yano, Y.; Kumadaki, I.; Yoshimura, K.; Enhancement of anticancer effect of alpha-tocotrienol by ether bond in phenolic hydroxy group of chroman ring. Vitamins, 2007, 81 (suppl), 181.
64. Yonezawa, Y.; Nagashima, Y.; Sato, H.; Virgona, N.; Fukumoto, K.; Shirai, S.; Hagiwara, H.; Seki, T.; Ariga, T.; Senba, H.; Suzuki, K.; Asano, R.; Hagiwara, K.; Yano, T. Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol. Carcinog., 2005, 43 (4), 188-197.
65. Johnson, F.M.; Saigal, B.; Tran, H.; Donato, N.J. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin. Cancer Res., 2007, 13 (14), 4233-4244.
66. Harris, A.L. Hypoxia-A key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2 (1) 38-47.
67. Brown, J.M.; Wilson, W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer, 2004, 4 (6), 437-447.
68. Denko, N.C.; Fontana, L.A.; Hudson, K.M.; Sutphin, P.D.; Raychaudhuri, S.; Altman, R.; Giaccia, A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene, 2003, 22 (37), 5907-5914.
69. Semenza, G.L. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J. Lab. Clin. Med., 1998, 131 (3), 207-214.
70. Ellis, L.M.; Staley, C.A.; Liu, W.; Fleming, R.Y.; Parikh, N.U.; Bucana, C.D.; Gallick, G.E. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem., 1998, 273 (2), 1052-1057.
71. Gray, M.J.; Zhang, J.; Ellis, L.M.; Semenza, G.L.; Evans, D.B.; Watowich, S.S.; Gallick, G.E. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene, 2005, 24 (19), 3110-3120.
72. Kashiwagi, K.; Harada, K.; Yano, Y.; Kumadaki, I.; Hagiwara, K.; Takebayashi, J.; Kido, W.; Virgona, N.; Yano, T. A redox-silent analogue of tocotrienol inhibits hypoxic adaptation of lung cancer cells. Biochem. Biophys. Res. Commun., 2008, 365 (4), 875-881.
73. Takenaga, K. Angiogenic signaling aberrantly induced by tumor hypoxia. Front Biosci., 2011, 16, 31-48.
74. Hagiwara, H.; Sato, H.; Shirai, S.; Kobayashi, S.; Fukumoto K.; Ishida, T.; Seki, T.; Ariga, T.; Yano, T. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells. Life Sci., 2006, 78 (19), 2249-2254.
75. Kozin, S.V.; Shkarin, P.; Gerweck, L.E. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res., 2001, 61 (12), 4740-4743.